Market Research Logo

Global Thrombocytopenia (Immune & Chemotherapy-induced) Market: Insights, Trends and Forecast (2019-2023)

Global Thrombocytopenia (Immune & Chemotherapy-induced) Market: Insights, Trends and Forecast (2019-2023)

The global immune thrombocytopenia (ITP) market is expected to reach 2.27 billion in 2023, growing at a CAGR of 5.82%, for the duration spanning 2019-2023. The factors such as, rising healthcare expenditures, growing female population, rising prevalence of arthritis, increasing incidences of hepatitis C and new cases of diagnosed cancer would drive the growth of the market. However, market growth would be challenged by the lethargic drug approval process, side effects associated with available thrombocytopenia drugs and the availability of alternative treatment options. A few notable trends include, novel drug development for thrombocytopenia, increasing number of awareness programs against thrombocytopenia, and increasing preferences for biosimilars.

The global thrombocytopenia market would witness considerable growth in coming years, due to the rising prevalence of thrombocytopenia and associated risk factors. The most common type of thrombocytopenia is ITP, which is highly prevalent in patients with rheumatoid arthritis. Whereas, CIT (Chemotherapy-Induced Thrombocytopenia) occurs in patients with cancer, due to the involvement of chemotherapy and radiation treatment. Thrombocytopenia in patients with CLD is growing rapidly with an increase in incidences of HCV infections among them.

The fastest growing regional market is the U.S., owing to the high prevalence of thrombocytopenia in patients with cancer as well as chronic liver diseases. Moreover, rising awareness about the symptoms and causes of thrombocytopenia among people, through various campaigns and the FDA approvals of various novel drugs for the treatment of thrombocytopenia would drive considerable growth in the global thrombocytopenia market.

Scope of the report:

  • The report provides a comprehensive analysis of the global thrombocytopenia (Immune and Chemotherapy-induced) market.
  • The major regional market (the U.S.) has been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Novartis AG, Merck and Co., CSL Limited, Amgen Pharmaceuticals, Horizon Therapeutics and Rigel Pharmaceuticals) are also presented in detail.
Key Target Audience:
  • Thrombocytes Drugs Manufacturers
  • Chemical Suppliers
  • End Users (Hospital, Medical Centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities


1. Overview
1.1 Introduction
1.2 Causes of Thrombocytopenia
Table 1: Causes of Thrombocytopenia
1.3 Symptoms of Thrombocytopenia
Table 2: Symptoms of Thrombocytopenia
1.4 Diagnosis of Thrombocytopenia
Table 3: Diagnosis of Thrombocytopenia
1.5 Treatment of Thrombocytopenia
Table 4: Treatment of Thrombocytopenia
1.6 Pathophysiology of Thrombocytopenia
2. Global Thrombocytopenia Market
2.1 Global ITP Market
2.1.1 Global ITP Market Forecast by Value
Table 5: Global ITP Market Forecast by Value (2019-2023)
2.1.2 Global ITP Total Patient Volume Forecast
Table 6: Global Total ITP Total Patient Volume Forecast (2019-2023)
2.1.3 Global ITP Total Patient Volume Forecast by Region
Table 7: Global ITP Total Patient Volume Forecast by Region (2023)
2.1.4 Global ITP Treated Patient Volume Forecast
Table 8: Global ITP Treated Patient Volume Forecast (2019-2023)
2.1.5 Global ITP Treated Patient Volume Forecast by Region
Table 9: Global ITP Treated Patient Volume Forecast by Region (2023)
2.2 Global CIT Market
2.2.1 Global CIT Total Patient Volume Forecast
Table 10: Global CIT Total Patient Volume Forecast (2019-2023)
2.2.2 Global CIT Total Patient Volume Forecast by Region
Table 11: Global CIT Total Patient Volume Forecast by Region (2018/2023)
2.2.3 Global CIT Treated Patient Volume Forecast
Table 12: Global CIT Treated Patient Volume Forecast (2018-2023)
2.2.4 Global CIT Treated Patient Volume Forecast by Region
Table 13: Global CIT Treated Patient Volume Forecast by Region (2018/2023)
3. Regional Thrombocytopenia Market
3.1 The U.S.
3.1.1 The U.S. ITP Total Patient Volume Forecast
Table 14: The U.S. ITP Total Patient Volume Forecast (2019-2023)
3.1.2 The U.S. ITP Treated Patient Volume Forecast
Table 15: The U.S. ITP Treated Patient Volume Forecast (2019-2023)
3.1.3 The U.S. Doptelet ITP Treated Patient Volume Forecast
Table 16: The U.S. Doptelet ITP Treated Patient Volume Forecast (2019-2023)
3.1.4 The U.S. CIT Total Patient Volume Forecast
Table 17: The U.S. CIT Total Patient Volume Forecast (2018-2023)
3.1.5 The U.S. CIT Treated Patient Volume Forecast
Table 18: The U.S. CIT Treated Patient Volume Forecast (2018-2023)
3.1.6 The U.S. Doptelet CIT Treated Patient Volume Forecast
Table 19: The U.S. Doptelet CIT Treated Patient Volume Forecast (2021-2026)
3.1.7 The U.S. CLD Patient Volume Forecast
Table 20: The U.S. CLD Patient Volume Forecast (2018-2023)
3.1.8 The U.S. CLD Patient Volume with Severe Thrombocytopenia Forecast
Table 21: The U.S. CLD Patient Volume with Severe Thrombocytopenia Forecast (2018-2023)
3.1.9 The U.S. CLD Treated Patient Volume with Severe Thrombocytopenia Forecast
Table 22: The U.S. CLD Treated Patient Volume with Severe Thrombocytopenia Forecast (2018-2023)
3.2 ROW (Rest of World)
3.2.1 ROW ITP Total Patient Volume Forecast
Table 23: ROW ITP Total Patient Volume Forecast (2019-2023)
3.2.2 ROW ITP Treated Patient Volume Forecast
Table 24: ROW ITP Treated Patient Volume Forecast (2019-2023)
3.2.3 ROW CIT Total Patient Volume Forecast
Table 25: ROW CIT Total Patient Volume Forecast (2018-2023)
3.2.4 ROW CIT Treated Patient Volume Forecast
Table 26: ROW CIT Treated Patient Volume Forecast (2018-2023)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising HealthCare Expenditure
Table 27: Global HealthCare Expenditure Per Capita (2014-2018)
4.1.2 Growing Female Population
Table 28: Global Female Population (2014-2018)
4.1.3 Rising Prevalence of Arthritis
Table 29: The U.S. Diagnosed Arthritis Population (2000-2020)
4.1.4 Increasing Incidences of Hepatitis C
Table 30: Hepatitis C Population in Major Regions (2018)
4.1.5 New Cases of Diagnosed Cancer
Table 31: Global New Cases of Diagnosed Cancer (2018)
4.2 Key Trends & Development
4.2.1 Novel Drug Development for Thrombocytopenia
Table 32: Novel Drug Development for Thrombocytopenia (2018)
4.2.2 Increasing Number of Awareness Programs about Thrombocytopenia
Table 33: Awareness Programs about Thrombocytopenia (2018)
4.2.3 Increase in Pharmaceutical R&D Expenditures
Table 34: Global Pharmaceutical R&D Expenditures (2014-2018)
4.2.4 Increasing Preference for Biosimilars
4.3 Challenges
4.3.1 Lethargic Drug Approval Process
Table 35: Drugs Approval Process
4.3.2 Side Effects Associated With Available Thrombocytopenia Drugs
4.3.3 Availability of Alternative Treatment Options
5. Competitive Landscape
5.1 Global Market
5.1.1 Key Players – Available Drugs for Chronic Thrombocytopenia
Table 36: Key Players - Available Drugs for Chronic Thrombocytopenia
5.1.2 Key Players – R&D Comparison
Table 37: Key Players - R&D Comparison (2017-2018)
5.1.3 Key Players - Revenue Comparison
Table 38: Key Players - Revenue Comparison (2018)
5.1.4 Key Players – Market Cap Comparison
Table 39: Key Players - Market Cap Comparison (2019)
6. Company Profiles
6.1 Novartis AG
6.1.1 Business Overview
6.1.2 Financial Overview
Table 40: Novartis AG Net Sales and Net Income (2014-2018)
Table 41: Novartis AG Net Sales by Segment (2018)
Table 42: Novartis AG Net Sales by Regions (2018)
6.1.3 Business Strategies
6.2 Merck & Co.
6.2.1 Business Overview
6.2.2 Financial Overview
Table 43: Merck & Co. Sales and Net Income (2014-2018)
Table 44: Merck & Co. Sales by Segment (2018)
Table 45: Merck & Co. Sales by Regions (2018)
6.2.3 Business Strategies
6.3 Amgen Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
Table 46: Amgen Inc. Total Revenue and Net Income (2014-2018)
Table 47: Amgen Inc. Total Revenue by Segment (2018)
Table 48: Amgen Inc. Total Revenue by Regions (2018)
6.3.3 Business Strategies
6.4 CSL Limited
6.4.1 Business Overview
6.4.2 Financial Overview
Table 49: CSL Limited Total Operating Revenue and Net Profit (2014-2018)
Table 50: CSL Limited Total Operating Revenue by Segment (2018)
Table 51: CSL Limited Total Operating Revenue by Regions (2018)
6.4.3 Business Strategies
6.5 Horizon Therapeutics
6.5.1 Business Overview
6.5.2 Financial Overview
Table 52: Horizon Therapeutics Net Sales and Net Loss (2014-2018)
Table 53: Horizon Therapeutics Net Sales by Segment (2018)
Table 54: Horizon Therapeutics Net Sales by Regions (2018)
6.5.3 Business Strategies
6.6 Rigel Pharmaceuticals
6.6.1 Business Overview
6.6.2 Financial Overview
Table 55: Rigel Pharmaceuticals Total Revenue and Net Loss (2014-2018)
Table 56: Rigel Pharmaceuticals Total Revenue by Divisions (2018)
6.6.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report